Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.43 |
| ▸ | CDK2 | P24941 | 4/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900029 | 1.00 | BTK (0.46) | BTKCHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL30673624 | 0.89 | HTR3A (0.38) | BTKCHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL9901829 | 0.89 | HTR3A (0.38) | BTKCHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL9900635 | 0.89 | HTR3A (0.38) | BTKCHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL7705836 | 0.81 | CHRNB4 (0.42) | — | |
| SCHEMBL28076460 | 0.78 | HRH4 (0.41) | ROCK1JAK2JAK1JAK3 | |
| SCHEMBL28563124 | 0.77 | TDO2 (0.37) | JAK2JAK1JAK3 | |
| SCHEMBL3462773 | 0.76 | KDM4E (0.44) | KCNH2 | |
| SCHEMBL3460358 | 0.76 | KDM4E (0.44) | KCNH2 | |
| SCHEMBL3460565 | 0.76 | KDM4E (0.44) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | BTK 19/4885CHEK1 1068/4885CCNA2 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.